The Global Health Body Sounds Concern Over Critical Lack of Obesity Medications
Fewer than 10% of patients that would benefit from GLP-1 drugs such as Wegovy can access them, states the global health agency as it issues its first guidance on the therapies.
Considering over a billion individuals worldwide now classified as obese, it is calling for increased and just access to this class of drugs.
According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The new guidance recognises that excess weight is a lifelong illness that can be addressed with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key obstacles to universal availability to the injections that can help people shift significant body mass, says the agency.
GLP-1 Therapy Supply Crisis
Even under the current most optimistic outlook, the manufacturing of these medications could only cover approximately 100 million people – less than 10% of eligible patients, per the health organization.
The guideline urges governments and firms to increase availability, through measures such as patent sharing.
Exclusive production rights on semaglutide – the primary component of a leading brand – is set to lapse in several nations in 2026.
The Way Obesity Injections Work
GLP-1 drugs mimick a body's own hormone to slow digestion, suppress the appetite and boost feelings of fullness so people consume fewer calories.
People typically see weight reduction within a few weeks of commencing the regular doses.
Studies suggests patients may regain a significant portion a year later of stopping the treatment, as their usual appetite resume.
Being overweight or obese raises your chance for contracting health problems, like type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.
Excess weight concerns people in every country and was associated with 3.7 million deaths worldwide in 2024, as per the WHO.
